USA flag logo/image

An Official Website of the United States Government

Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93510
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA137737
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANDROBIOSYS, INC.
875 Ellicott St BUFFALO, NY 14203-1070
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ
Agency: HHS
Contract: 1R43CA137737-01
Award Amount: $139,945.00
 

Abstract:

DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the techno logy for reproducible implantation of primary xenografts of benign and malignant human prostate and kidney tissue. Xenografts have been established from over two hundred and fifty successive fresh surgical specimens and are characterized by maintenance of the tissue architecture of the tissue in the human donor, including the maintenance of a completely human vascular network and tissue microenvironment. The vascular endothelial cells of primary xenografts of benign and malignant human prostate tissue demon strate active angiogenesis, express functional androgen receptor protein, and undergo a wave of apoptotic death upon androgen deprivation that precedes by several days the wave of apoptotic death of prostate epithelial or prostate cancer epithelial cells. In contrast, while the endothelial cells in primary xenografts of benign human kidney tissue or human renal cell carcinoma tissue are of human origin, the endothelial compartment demonstrates minimal angiogenic potential, does not express AR and does not u ndergo apoptotic death in response to androgen deprivation. Lastly, in support of the in vivo xenograft model, AndroBioSys has developed the expertise to establish primary cultures of human epithelial, stromal and endothelial cells from fresh surgical spec imens of benign and malignant prostate and kidney tissue for prediction and/or verification of in vivo studies in matching primary xenografts. The goal of this application to the IMAT Program is to validate this in vitro/in vivo pre-clinical model system a s a tool for analysis at the molecular level of: inter-individual differences in host biology; differences between the biology of individual cancers; and inter-individual differences in the host micro- environmental compartments. In addition, the Phase I p rogram will evaluate the utility of this model for analysis of treatment modalities that target the human endothelial cell/vascular barrier, as a mechanism to modulate the bio-availability and response to therapeutic modalities, focusing on molecular endpo ints measurable at the cellular, tissue and systemic (host serum) levels.

Principal Investigator:

Michael G. Zwick
7168607920
MZWICK@ANDROBIOSYS.COM

Business Contact:


mzwick@androbiosys.com
Small Business Information at Submission:

ANDROBIOSYS, INC.
ANDROBIOSYS, INC. 73 HIGH ST BUFFALO, NY 14203

EIN/Tax ID: 202315778
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No